CAMBRIDGE, Mass. (AP) _ Epizyme Inc. (EPZM) on Tuesday reported a loss of $35.7 million in its second quarter.

The Cambridge, Massachusetts-based company said it had a loss of 21 cents per share.

The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 36 cents per share.

The biopharmaceutical company posted revenue of $27.5 million in the period, also beating Street forecasts. Three analysts surveyed by Zacks expected $10.1 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EPZM at https://www.zacks.com/ap/EPZM

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News